Objective: Healthcare professionals (HCPs) are required to assess and train patients in the correct use of inhalers but are often unable to demonstrate correct technique themselves. We sought to assess the level of training required for HCPs to master and maintain device mastery when using two different dry powder inhalers (DPIs). Methods: We conducted a randomised, un-blinded, cross-over study in undergraduate HCPs who undertook a stepwise training (from step 1, intuitive use, to step 6, expert tuition) in the use of Turbuhaler ® (an established device) and Spiromax ® (a newer, reportedly easier to use device). Device mastery (absence of errors) was evaluated by expert assessors at each step. Maintenance of device mastery was assessed 4 ± 1 week (visit 2) and 8 ± 2 weeks (visit 3) after initial training (visit 1). respectively; p<0.001). Conclusions: There are significant differences in the nature and extent of training required to achieve and maintain mastery for different DPIs. The implications of this on clinical practice, device education delivery and patient outcomes require further evaluation.
Introduction
Inhalers are the most commonly used devices to deliver pharmacological treatments for asthma and chronic obstructive pulmonary disease (COPD). Because correct use of inhalers is central to effective therapy, poor inhaler technique not only compromises disease control [1] but also consequently increases the economic burden of asthma management [2] . Unfortunately, incorrect inhaler use remains common in clinical practice [3] and this aspect has not improved over the past 40 years [4] . This has prompted international organisations of clinicians and health care providers to recognise the importance of patient education by healthcare professionals (HCPs) [5] . The Global Initiative for Asthma (GINA) Guidelines recommend training patients in the use of inhalers as a fundamental and essential component of good clinical practice and consequently advise that HCPs assess and train patients in inhaler use at every clinical encounter [6] . Research has shown that face-to-face training substantially improves patients' ability to use their inhalers correctly [7, 8] . However, as shown by previous studies, many HCPs lack the basic knowledge and technical skill to teach different inhaler techniques [9] [10] [11] and they seldom receive formal training in the use of inhalers [12] . Finding solutions to this major problem is of utmost importance to improve the control of asthma and COPD in the population [13] . While it is important to explore the way in which HCPs are currently trained in the use of inhalers, at present it is unfortunately unrealistic to believe that (as is the requirement for patients) each HCP will have the opportunity to receive hands-on individualised training. This puts the onus on each individual HCP and this is where more intuitive devices might be of help. Many of the newer devices are reported to be easier to use [14] [15] [16] ; however, it is still unknown what this actually means for HCPs. While HCPs have been shown to retain device mastery more efficiently when they have the opportunity to educate their patients [17] , it appears important to assess the impact of newer and allegedly more intuitive devices on their ability to retain mastery over time.
The aim of this study was to assess the nature and extent of training required for HCPs to master and maintain correct inhaler technique when using two different dry powder inhalers (DPIs), in particular comparing the role of newer, reportedly simpler to use DPIs with that of more established DPIs. To address these research questions, we conducted a randomised, un-blinded, cross-over study in pharmacist, physician and nursing undergraduates and compared Spiromax ® (an example of a newer device) with Turbuhaler ® (an example of an established device). These two particular inhalers were chosen as relevant comparators on the basis that they are both DPIs licensed in Europe for the delivery of budesonide/formoterol combination therapy for asthma but differ in terms of design and dose preparation steps.
Methods

Study design and subjects
This was a multi-centre, randomised, un-blinded, cross-over study conducted between July 2014
and June 2015 (ClinicalTrials.gov Identifier: NCT02570425). Participants were recruited via relevant e-learning websites, promotion of the study at lectures, and provision of participant information at tutorials. Students who chose to participate in the study were screened for eligibility and enrolled if they met the following inclusion criteria:
provided written and informed consent; were willing to comply with study restrictions and attend study visits as specified; were enrolled in one of the specified University departments; had not used or received training in the use of either Turbuhaler ® or Spiromax ® in the last 6 months.
Potential participants were excluded from the study if they had a current diagnosis of asthma, a past diagnosis of asthma, or both. [20] . For both devices, we compiled a checklist of errors potentially impairing drug delivery to the lungs. These errors were identified a priori based on the manufacturer's instructions included in the patient information leaflet [18, 20] and on expert steering committee advice [21] . The checklists include errors associated with dose preparation, position of the inhaler, inhalation manoeuvre, and general knowledge of device use (Table S1 ).
Study devices
Study procedures
The study consisted of three visits over a period of 8 ± 2 weeks. At each visit, and before starting any procedure, baseline data (demographic characteristics and history of inhaler device use prior to study) were collected.
At visit 1, participants were randomly assigned to either Turbuhaler ® training followed by Spiromax ® training or Spiromax ® training followed by Turbuhaler ® training (cross-over design) ( Figure 1 ). The training procedure was designed to represent best clinical practice, current available mode of education, and to address the educational needs of HCPs. It consisted in a stepwise process in which participants were assessed on their ability to use the device through 6 consecutive steps: (1) intuitive use; (2) use of patient information leaflet; (3) use of instructional video; (4) expert tuition; (5-6) repeats of expert tuition (see Table S2 for details of instructions provided at each step). At each step, participants were monitored by expert assessors specifically trained to provide education and feedback to device users; errors in device use were recorded according to the device checklist (Table S1 ). Participants progressed from one step to the next until they achieved device mastery (defined as the ability to demonstrate inhaler use without assessor-observed errors) or until completion of all 6 training steps ( Figure 2 ). They then proceeded to complete the same training and assessment process with the second empty device.
At the end of the visit, participants were asked to rate their satisfaction for each device by completing Part II question 15 of the Patient Satisfaction and Preference Questionnaire (PASAPQ). PASAPQ is a multi-item measure of satisfaction and preference for respiratory inhalation devices [22] .
Visits 2 and 3 commenced 4 weeks (± 1 week) and 8 weeks (± 2 weeks) after visit 1, respectively.
Participants were once again randomly assigned to receive step-by-step device training on Turbuhaler ® followed by Spiromax ® or Spiromax ® followed by Turbuhaler ® to determine whether device mastery had been maintained over the 4-and 8-week time period. If they did not maintain device mastery at step 1, participants were trained as in visit 1 until device mastery was reestablished. Device preference was again assessed using the PASAPQ Part II question 15 at the end of the visit.
Study definitions and outcomes
Device mastery (yes/no) was defined as the ability to demonstrate inhaler use without assessorobserved errors. Maintenance of device mastery, assessed at visits 2 and 3, was defined as the ability to demonstrate correct inhaler use without the need to undertake any further training (i.e., no errors at step 1).
The primary outcome was maintenance of device mastery at visit 2. Secondary outcomes included maintenance of device mastery at visit 3 and, for each visit, the following: achievement of device mastery by steps 1, 2, and 3; number of steps required to achieve mastery; number and type of errors made; and participants' preference for the inhaler.
Statistical analyses
Data were analysed using Statistical Analysis Software version 9.3 (SAS Institute Inc). The study was powered on the primary outcome, maintenance of device mastery at visit 2. Based on results from a similar study [7] , a sample size of 137 pairs (137 subjects evaluated on both inhalers) was Wilcoxon signed rank tests were used to compare the proportion of participants achieving device mastery stratified by the order of randomisation and the mean/median number of levels required to achieve device mastery between the two devices, respectively. For all analyses where P-value is provided, statistical significance was set at 0.05.
Summary statistics collected at each visit included: number of levels required to achieve device mastery, number and type of assessor-observed errors (total of errors made at all steps) and device preference. Continuous variables (including age and number of levels taken to achieve device mastery) were summarised by reporting their mean/median along with their standard deviations/interquartile range (IQR). Categorical variables were reported as frequencies and percentage proportions. In particular, device mastery (yes/no) was expressed as cumulative number and percentage of participants achieving device mastery by each training step, unless otherwise stated. Participant demographic and baseline characteristics were summarised using descriptive statistics.
Results
Participant disposition and characteristics
A total of 542 participants were enrolled in the study; of these, 516 (39% male, mean age 23 ± 5 years) met the eligibility criteria and were randomised into visit 1. Four hundred ninety-eight and 460 participants were eligible for visits 2 and 3, respectively. Figure S1 and Table S3 show the disposition and the demographic characteristics of participants at each visit of the study, respectively.
Achieving device mastery
At visit 1, the odds of making a device error prior to training was significantly lower for (Table   1 ). Likewise, a significantly higher number of participants achieved mastery in the use of Spiromax ® by steps 2 and 3 (p<0.001). This effect was independent of device randomisation order (steps 1 and 2, p<0.001 for both randomisation orders; step 3, p<0.05 for both randomisation orders; Chi-squared test) ( Table 1 ). By step 4 (expert tuition), about 90% of participants achieved device mastery, with no statistical difference between the devices (data not shown).
At visit 1, the median number of steps required to achieve device mastery was 2 (patient information leaflet; [IQR] 2-4) for Spiromax ® and 3 (instructional video; IQR 2-4) for Turbuhaler ® (p<0.001; Wilcoxon Signed-Rank test).
Maintaining device mastery
Visit 2
At visit 2, a total of 317 (64%) participants had maintained device mastery with Spiromax Table 2 ). This effect was independent of device randomisation order ( McNemar's test of paired data). This effect was associated with device randomisation order: at both steps, significantly more participants using Spiromax ® as first device achieved device mastery compared with participants using Turbuhaler ® as first device (p<0.001 and p=0.007 for steps 2 and 3, respectively; Chi-squared test); however, there was no significant difference in device mastery when Spiromax ® and Turbuhaler ® were used as second device (step 2, p=0.347; step 3, p=1.00) ( Table 2 ). The median number of steps required to achieve device mastery was 1 (intuitive use; IQR 1-2) for Spiromax ® and 2 (patient information leaflet; IQR 1-2) for Turbuhaler ® (p<0.001; Wilcoxon Signed-Rank test).
Visit 3
At visit 3, a total of 362 (79%) participants maintained device mastery on Spiromax ® prior to training compared with 299 (65%) participants who maintained device mastery on Turbuhaler ® (p<0.001; McNemar's test of paired data); this effect was independent of device randomisation order ( Table 3 ). The odds of making a device error was significantly lower for Spiromax Already by step 2, over 90% of participants demonstrated device mastery on both inhalers with no significant difference between the two devices (Table 3) . Likewise, there was no significant difference in the median number of steps required to achieve device mastery between the two devices (median number of steps 1, IQR 1-1 for Spiromax ® and 1-2 for Turbuhaler ® ; p=0.111;
Wilcoxon Signed-Rank test). Figure 3 summaries the proportion of participants achieving and maintaining device mastery over the study period.
Number and types of errors made
At each visit, a significantly higher number of errors were made on Turbuhaler ® than on Spiromax ® (total number of errors made at all steps: 2540 vs 1447 at visit 1; 780 vs 367 at visit 2;
296 vs 175 at visit 3). The most common device errors made at each visit are reported in Table 4 .
The error 'not twisting the base as far as possible' related to dose preparation was the most steps for preparing the dose. In terms of the level of training required to achieve mastery, we made the following observations: 1) at visit 1, 60% of participants using Spiromax ® achieved mastery with written information, whereas for Turbuhaler ® a video instruction was required for a comparable proportion of participants to achieve mastery; 2) although many participants were able to achieve device mastery after the first three steps of training, some participants did require additional training through individualised feedback to achieve mastery. These findings have practical implications as they suggest that for Spiromax ® the written instructions provided in package inserts are sufficient to train a substantial percentage of individuals whereas, for [14] and patients with asthma [23] . This may have implications for clinical practice, as patients' preference may affect adherence and thus is an important factor that HCPs are encouraged to consider when prescribing/switching inhalers [24] .
When taking randomisation order into account, we observed a learning effect. During initial training (visit 1), for both Spiromax ® and Turbuhaler ® the percentage of participants demonstrating device mastery when the inhaler was used as the second device was higher than the percentage of participants demonstrating mastery when the inhaler was used as the first device.
This was true for steps 1, 2 and 3 though at step 1 the percentage increased by three and six times Basheti et al [26] , our checklists were generated by expert opinion and included errors that have been used in previous studies [14] . The errors considered here are those commonly seen in clinical practice, which have potential implications on device effectiveness; however, they are not a validated measure. Although some studies have investigated the impact of inhaler misuse or the number of inhaler errors on asthma control [3, 25] and management [1] , knowledge of the relationship between individual inhaler errors and asthma outcomes is still limited. This knowledge would be crucial to better identify critical errors and develop educational interventions for HCPs and patients tailored to address such errors specifically.
There are some limitations in the study design. This was primarily an 'evaluation-of-concept' study that analysed a cohort of undergraduate HCPs with a mean age of 23. This is a very specific cohort and thus our findings may not be generalisable to patients with chronic airways disease or to practicing HCPs.
Conclusions
This study shows that there are significant differences in the nature and extent of training required for HCPs to achieve and maintain mastery with different DPI devices. Inhalers that are easier to use may facilitate achievement of device mastery and its maintenance over time. Expert tuition during initial training may help to optimise HCP knowledge of inhaler use to the extent that refreshing HCP skills with minimal instructions (such as written instructions) may be sufficient to maintain correct technique over time. Future research should explore the impact of tailored education for HCPs on the health care system in terms of clinical and economic outcomes.
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Figure 2: Inhaler technique assessment and training
At each study visit, participants were assessed on their ability to use the empty study devices without training followed by training in a step-wise approach. Training consisted of 6 consecutive steps: step 1, intuitive use; step 2, use of patient information leaflet; step 3, use of instructional video; steps 4-6, expert tuition. Participants progressed from one step to the next until device mastery was achieved (defined as absence of assessor-observed serious errors) or until all 6 steps were completed. Upon attainment of device mastery, participants proceeded to complete the same training and assessment procedure with the second empty device.
Abbreviations: HCPs = healthcare professionals. The chart shows the cumulative proportion (%) of participants demonstrating correct inhaler technique with the two study devices at each step during the study visits. Total number of participants: visit 1, n=516; visit 2, n=498; visit 3, n=460. Data are expressed as cumulative n (%) of participants maintaining/achieving device mastery by each step. Device mastery (yes/no) was defined as the ability to demonstrate inhaler use without assessor-observed errors. As at steps 2-3, also at steps 4-6 (not shown) no significant difference was detected between the devices. 
